Key Highlights
- Oxford Nanopore Technologies (LSE:ONT) rose 4.60% to close at 209.2p on 19 October 2026, among the top FTSE 250 risers.
- The shares have nearly doubled from summer lows near 106.5p, when the company warned that first-half revenue would miss expectations.
- Full-year 2026 guidance of 21% to 25% constant currency revenue growth has been maintained.
- The group still targets adjusted EBITDA breakeven in 2027, a key milestone for investors.
- Monday's gain also supported shares of IP Group, a long-standing shareholder in the business.
Why Oxford Nanopore Is in Focus Today
Oxford Nanopore Technologies (LSE:ONT) continued its remarkable recovery on Monday, rising 4.60% to close at 209.2p and ranking among the best performers on the FTSE 250. The gain came even as the mid-cap index slipped 0.63% and the FTSE 100 suffered a 1.1% drop, making the DNA and RNA sequencing specialist one of the most notable healthcare movers of the day.
The latest move adds to an extraordinary turnaround. In July, Oxford Nanopore shares plunged around 11% to 106.5p after the company warned that revenue for the six months to 30 June would come in at about £116.5 million, below market expectations, mainly because of weaker trading in China and the Middle East. Since then the stock has almost doubled, reflecting renewed confidence in its long-term growth and its path to profitability.
From Summer Slump to Autumn Rally
The July warning highlighted specific pressures. Revenue in China declined around 16%, reflecting tighter export control restrictions and changes to commercial operations, while Middle East sales fell 14%. Timing of orders and contract wins in the Americas also weighed. Outside China and the Middle East, however, revenue growth was a healthy 16% at constant currency, with Europe, Middle East, India and Africa up 23% and the Americas up 12%.
Crucially, Oxford Nanopore Technologies (LSE:ONT) kept its full-year 2026 guidance of 21% to 25% constant currency revenue growth, supported by expected non-recurring collaboration and licensing revenue in the second half. That reassurance, combined with a lower share price, appears to have drawn in long-term investors who see value in a business with unique long-read sequencing technology.
The Profitability Milestone Investors Want
For years the debate around Oxford Nanopore has focused on when the company would stop burning cash. Management has maintained a target of reaching adjusted EBITDA breakeven in 2027, and investors have been encouraged that this goal remains intact despite softer first-half trading. Analysts at Berenberg have previously described the path to profitability as on track while keeping a buy stance.
Corporate interest has also been part of the narrative. Co-founder and chief executive Gordon Sanghera has previously acknowledged that the company could be exposed to takeover interest given its depressed valuation, with large diagnostics groups seen as potential suitors. While there is no active bid, that possibility helps support sentiment whenever the shares look cheap relative to their technology.
Wider Market and Sector Context
Monday's market was dominated by risk aversion, with banks and miners under pressure and investors cautious ahead of major US technology earnings. Healthcare and life sciences stocks with strong growth stories and identifiable catalysts stood out. Oxford Nanopore's rise also lifted interest in IP Group, which holds a significant stake in the sequencing company.
The genomics sector globally has faced challenges, including funding pressures for research customers and geopolitical tension affecting sales into China. However, demand from clinical, applied and biopharma markets continues to expand, and Oxford Nanopore's portable, real-time sequencing devices give it a distinctive position in areas such as infectious disease surveillance and rapid diagnostics.
What Investors Are Watching Next
The key near-term focus is whether second-half trading delivers the growth needed to hit full-year guidance, including the collaboration and licensing revenue the company has flagged. Any update on Chinese sales and the impact of export controls will be scrutinised, as will order trends in the Americas.
Investors will also track progress on gross margin improvement and operating cost discipline, both essential to the 2027 EBITDA breakeven goal. A trading update around the turn of the year is expected to provide the next major data point. For now, Oxford Nanopore Technologies (LSE:ONT) remains one of the most volatile and closely followed growth stocks on the FTSE 250, and any fresh contract wins, product launches or partnership announcements could quickly move the shares again in the weeks ahead.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...